Drug Discovery Featured Articles & Applications
-
TYK2 Inhibition Emerges As A Next-Gen Strategy To Treat PsA
7/10/2025
The treatment landscape for psoriatic arthritis (PsA) is evolving rapidly, with data presented at EULAR 2025 signaling a new chapter in disease management with the emergence of a selective tyrosine kinase 2 (TYK2) inhibitor.
-
Multi-Indication Strategies Reshape Immunology's R&D Strategy
7/10/2025
A clear trend at EULAR 2025 emerged across presentations and pipelines: leading biopharma players are increasingly embracing multi-indication strategies, designing assets to work across dermatology, rheumatology, and gastroenterology indications.
-
Immunology's Next Frontier: High-Risk, High-Reward Innovations From EULAR 2025
7/10/2025
The 2025 European Congress of Rheumatology (EULAR) showcased a shift in immunology, highlighting a convergence of next-generation mechanisms and novel therapeutic modalities. Of note is the emergence of cell therapies as a treatment strategy.
-
New Regulatory Considerations For Animal Testing And The Consequences For Drug Product Formulation Development
7/3/2025
The U.S. is experiencing a shift in the regulatory environment for animal testing, driven by the evolving use of AI. This impacts the formulation development approach for new drugs in the non-clinical phase.
-
From Undruggable To Druggable: The Science Reshaping Small Molecule Discovery
7/1/2025
For decades, most biologically validated disease-relevant protein targets have remained chemically inaccessible, thereby resisting conventional small molecule approaches. But now, a new wave of scientific innovation is paving a way forward.
-
Five Takeaways from BIO 2025 and Why You Should Stay Tuned
6/26/2025
New chief editor of Drug Discovery Online shares insights from BIO 2025’s global biotech gathering and spotlights the impacts to early-stage drug research.
-
From Matrix To Medicine: New Frontiers In Treating Pulmonary Fibrosis And PH
6/25/2025
Halo Biosciences is building a pipeline based on novel insights into how extracellular matrix dysregulation drives disease. We caught up with its leaders to discuss their approach to drug targeting and early development.
-
Tackling Antimicrobial Resistance With Precision Targeting
6/20/2025
TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance. We caught up with the company's CEO and CSO to discuss their approach to early R&D.
-
Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet
6/19/2025
This scientific article presents a summary of the formulation development strategy of a JAK1 inhibitor extended-release tablet, with a focus on experimental design, data interpretation, and formulation decision-making.
-
A Guide To Designing mRNA Medicines
6/10/2025
A poorly designed mRNA sequence can create ongoing difficulties during downstream clinical development and manufacture. Let's take a closer look at strategies and design software that you can employ.